Medicare Advantage’s Discipline Era — and Why the Final Rate Notice Matters More Than It Appears

The challenge for policymakers is balance: encouraging rigor without unintentionally weakening a program that now serves the majority of Medicare beneficiaries. Thoughtful rate calibration can determine whether this transition strengthens the program or strains it unnecessarily. The post Medicare Advantage’s Discipline Era — and Why the Final Rate Notice Matters More Than It Appears appeared…

Read More

2026: A Year for Reimagining Healthcare’s Safety Net

By JEFF BRANDES To say healthcare’s safety net experienced tectonic shifts in 2025 would be an understatement. The rapid introduction of multiple and massive policy shifts left many healthcare leaders reeling with more questions than answers. As the industry turns the corner into 2026 and the dust begins to settle, it’s time for stakeholders to…

Read More

How to stop the measles outbreak in South Carolina?

Simple: get people vaccinated. Dr. Oz agrees. The New York Times reports: Dr. Oz, the Centers for Medicare and Medicaid Services director, told CNN on Sunday that there was a simple solution to the raging measles outbreak in South Carolina, which has infected more than 900 people and become the largest U.S. outbreak in recent…

Read More

Trust No One

By KIM BELLARD You know, it’s gotten to the point when I just try to tune out the things Robert F. Kennedy Jr. says. “Schizophrenia can be cured with a keto diet”? Sure, whatever. “The war on protein is over”?  Who even knew there was such a war? The carnivore diet is a great way…

Read More

Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis

Evommune’s EVO301 met the goals of a placebo-controlled Phase 2a study in atopic dermatitis. The biologic drug neutralizes a signaling protein involved in multiple inflammatory pathways, which could differentiate it from the blockbuster Sanofi and Regeneron Pharmaceuticals immunology drug Dupixent. The post Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis…

Read More